Summary of Significant Accounting Policies (Tables)

6 Months Ended

Dec. 31, 2025

Summary of Significant Accounting Policies

Schedule of vendor concentration risk percentage


		Three Months Ended						Six Months Ended
		December 31,						December 31,
		2025			2024			2025			2024
Vendor A		27	%		27	%		27	%		26	%
Vendor B		10	%		10	%		10	%		10	%

Schedule of revenue by geographical region


		Three Months Ended
		December 31,
		2025						2024
United States		$	6,698,701		56.8	%		$	6,932,120		58.2	%
Europe			3,867,252		32.8	%			3,730,368		31.3	%
Rest of World			1,226,698		10.4	%			1,251,731		10.5	%
Total		$	11,792,651		100	%		$	11,914,219		100	%

Schedule of accounts receivable by geographical region


		As of December 31, 2025						As of June 30, 2025
United States		$	2,985,621		52.7	%		$	4,033,807		56.1	%
Europe			2,054,074		36.3	%			2,413,906		33.6	%
Rest of World			621,476		11.0	%			743,521		10.3	%
Total		$	5,661,171		100	%		$	7,191,234		100	%

Schedule of segment reporting information


		Three Months Ended						Six Months Ended
		December 31,						December 31,
		2025			2024			2025			2024
Revenue		$	11,792,651		$	11,914,219		$	24,104,836		$	23,958,701
Cost of revenue			5,615,701			6,093,126			11,702,588			12,371,732
Gross profit			6,176,950			5,821,093			12,402,248			11,586,969
Gross profit margin			52.4%			48.9%			51.5%			48.4%
Selling, general and administrative expenses:
Sales and marketing			1,648,598			1,343,087			3,315,423			2,533,494
Technology and product development			1,602,421			1,506,849			3,012,572			2,879,607
General and administrative			1,620,595			2,008,201			3,295,954			3,938,377
Stock-based compensation expense			213,449			534,322			425,931			952,311
Foreign currency transaction loss (gain)			36,112			29,554			18,856			(74,686)
Total selling, general and administrative expenses			5,121,175			5,422,013			10,068,736			10,229,103
Depreciation and amortization			316,425			306,233			632,491			618,328
Net income (loss)		$	546,919		$	(1,980,234)		$	1,296,306		$	(1,311,230)


		As of December 31, 2025			As of June 30, 2025
Cash and cash equivalents		$	12,262,780		$	12,227,312
Current assets, excluding cash and cash equivalents			6,411,401			7,772,416
Long term assets			25,569,699			26,120,946
Total segment assets		$	44,243,880		$	46,120,674

Schedule of earnings per share, basic and diluted


		Three Months Ended						Six Months Ended
		December 31,						December 31,
		2025			2024			2025			2024
Net income (loss) available to common shareholders		$	546,919		$	(1,980,234)		$	1,296,306		$	(1,311,230)

Weighted average commons shares - basic			31,634,575			30,421,808			31,434,725			30,384,339
Dilutive effect of outstanding stock options			672,107			—			661,435			—
Dilutive effect of unvested restricted common stock			26,975			—			17,248			—
Weighted average commons shares - diluted			32,333,657			30,421,808			32,113,408			30,384,339

Net income (loss) per common share:
Basic		$	0.02		$	(0.07)		$	0.04		$	(0.04)
Diluted		$	0.02		$	(0.07)		$	0.04		$	(0.04)

Schedule of Company's assets and liabilities at fair value


		As of December 31, 2025												As of June 30, 2025
		Level 1			Level 2			Level 3			Total			Level 1			Level 2			Level 3			Total

Assets
Total assets		$	—		$	—		$	—		$	—		$	—		$	—		$	—		$	—

Liabilities
Contingent earnout liability		$	—			—		$	10,700,952		$	10,700,952		$	—			—		$	14,046,640		$	14,046,640
Total liabilities		$	—		$	—		$	10,700,952		$	10,700,952		$	—		$	—		$	14,046,640		$	14,046,640

Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.

+ References + Details